Human Genome Sciences Inc. clinical trials

Acquired by GlaxoSmithKline, Jul 2012 · source ↗

The registry lists 36 studies whose lead sponsor is Human Genome Sciences Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 8, 2021.

Studies

Recruiting first, then most recently updated. Showing 36 of 36. All GlaxoSmithKline studies →

• Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)CompletedNCT01632241Phase 4

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompletedNCT01639339Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · Unclear whether first submitted before or after Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057CompletedNCT00712933Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02CompletedNCT00583362Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaCompletedNCT01258608Phase 1/2

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With ReinjectionCompletedNCT02016963Phase 2/3

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted after Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy SubjectsCompletedNCT00639678Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01597492Phase 4

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01484496Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Belimumab in Remission of VASculitisCompletedNCT01663623Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted after Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Belimumab in Subjects With Systemic Lupus ErythematosusCompletedNCT00410384Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00424476Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United StatesCompletedNCT00724867Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid TumorsCompletedNCT00708006Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1CompletedNCT00115908Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)CompletedNCT00071812Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung CancerCompletedNCT00583830Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT00315757Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3CompletedNCT00411385Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive PatientsCompletedNCT00402428Phase 3

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Study of Belimumab Administered Subcutaneously to Healthy SubjectsCompletedNCT01583530Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)TerminatedNCT00732940Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01TerminatedNCT00583557Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00071487Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative ColitisWithdrawnNCT01434576Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)CompletedNCT00094848Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis CCompletedNCT00097435Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01013818Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00092924Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral TherapyCompletedNCT00114699Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3CompletedNCT00656006Phase 2

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00657007Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc. · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) StudiesCompletedNCT01858792

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted after Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid MalignanciesSuspendedNCT01604863Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99No longer availableNCT00931086

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline

• A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaCompletedNCT00712855Phase 1

  Sponsor listed in the registry: Human Genome Sciences Inc., a GSK Company · First submitted before Human Genome Sciences Inc. became part of GlaxoSmithKline